This inventor holds 1 USPTO granted patent. Top assignee: National Defense Medical Center. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Kuang-ming Cheng: Innovator in Nanoparticle Technology
Introduction
Kuang-ming Cheng is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of nanoparticle technology, particularly in the development of innovative materials for medical applications. His work focuses on enhancing the delivery of therapeutic agents to cells, which has important implications for immunology and drug delivery systems.
Latest Patents
One of Kuang-ming Cheng's key patents is titled "Fucoidan-quaternized chitosan nanoparticles and application thereof." This invention relates to the creation of fucoidan-quaternized chitosan nanoparticles, which serve as an immunogenic composition. The patent outlines a method for delivering agents to cells using these nanoparticles, showcasing his expertise in combining biochemistry with nanotechnology. He holds 1 patent in this area.
Career Highlights
Kuang-ming Cheng is affiliated with the National Defense Medical Center, where he applies his research to advance medical technologies. His work at this institution emphasizes the importance of innovation in defense-related medical applications, particularly in enhancing the efficacy of treatments through novel delivery systems.
Collaborations
Throughout his career, Cheng has collaborated with esteemed colleagues such as Jenn-jong Young and Jyh-Hwa Kau. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further driving innovation in their respective fields.
Conclusion
In summary, Kuang-ming Cheng is a pioneering inventor whose work in fucoidan-quaternized chitosan nanoparticles represents a significant advancement in medical technology. His contributions are vital for the future of targeted drug delivery and immunogenic therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile